Basem Goueli MD/PhD/MBA

CancerClarity

We are in our early stages in the development of CancerClarity, which is in the clinical trial, pharmaceutical consulting, cancer center consulting, and clinical treatment forums.  We are presently in stealth mode.

CEO and Founder

CancerLight

We are in the early stages of developing CancerLight, a company in the patient education space.  We are presently in stealth mode.

Catholic Health

Medical director of hematology/medical oncology for Catholic Health System.

Medical Director of Hematology/Medical Oncology

Great Lakes Cancer Care

Director of Hematology and Medical Oncology

University at Buffalo

Associate Chief of Hematology/Medical Oncology

Covenant Health/Thompson Oncology Group

St. Luke's Reginoal Cancer Center

Director

I have directed three independent cancer institutes, collectively representing 17 hospitals and 12 cancer centers.  I am a hematologist and medical oncologist who has been the institutional principal investigator on nearly 100 clinical trials involving breast cancer, myeloma, prostate cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, myelodysplastic syndrome, CLL, DLBCL, esophageal cancer, etc.  I was on three papers published in The New England Journal of Medicine (prostate cancer, chronic neutrophilic leukemia, lung cancer) and two in Lancet (Shingles vaccine and head and neck cancer).  I am board certified in hematology, medical oncology, internal medicine, and artificial intelligence in medicine.


As depicted in my profile, my training background includes:
MD:  Mayo Clinic
PhD in biochemistry:  Mayo Clinic
MBA:  University of North Carolina, Chapel Hill
Internal Medicine Residency:  George Washington University Hospital with 4 months at the NIH
Hematology/Oncology Clinical Fellowship:  Stanford
Biochemistry Post-Doctoral Fellowship:  Stanford
MIT Xpro Course Certificate:  Designing Artificial Intelligence Products 
MIT Xpro: Course Certificate:  Robotics Essentials 
MIT Xpro: Course Certificate:  Drug and Medical Device Development 
MIT Professional Education Course Certificate:  Applied Data Science Bootcamp

I resisted the trend towards subspecialization in my career as I feel ideation often happens at the level of the forest, not the trees.  Many of the greatest future innovations will be at the interface of various disciplines. 

My area of clinical expertise is precision medicine, and my ability to treat patients in all hematology/medical oncology disciplines uniquely positions me to sequence molecular-based therapies in the context of conventional therapy and clinical trials.

I am the CEO and Founder of three companies:  CancerClarity, CancerLight, and Revolution Cancer Medical Care PLLC.  We are early in our development as we hope to disrupt the clinical trial, patient education, and clinical care forums.  Aside from building my two companies, I am a consulting medical director for 2 phase 1 Xbiotech clinical trials (pancreatic cancer), consult for numerous other pharmaceutical companies, and see patients full-time in the clinic as a hematologist/medical oncologist.  I recently turned down several high-visibility positions to pursue my vision.

My singular focus is to help as many people as I can in the shortest time frame possible.

#1 Most Followed Voice in AI Business (1.5M) | Leading AI Entrepreneur & Advisor | Former Amazon, IBM | LinkedIn Top Voice | @alliekmiller on Instagram, X, TikTok

I help life science, biotech, and tech-driven organizations turn complex expertise into clear, credible LinkedIn presence and thought leadership that drives real business outcomes.

I’m a former scientist and marketing executive, now a tech & business writer/editor, published in Forbes. Today, I run a specialized ghostwriting and content strategy agency, AB Research & Media, where I work with VC funds, publicly traded biotech companies (including NASDAQ-listed), CROs, and founders.

In addition to agency work, I consult 1:1 with life science organizations and senior leaders on LinkedIn strategy—helping them:

- clarify positioning in crowded, technical markets

- translate scientific depth into executive-level narratives

- build credibility without turning leaders into “content influencers”

- use LinkedIn as a strategic channel for visibility, partnerships, and deal flow

I currently write “The Biotech Edge,” one of the leading LinkedIn newsletters in the techbio space, read by 24,000+ industry professionals. I collaborate with companies building technologies for biomedical and life-science markets through sponsored issues and long-term content partnerships.

I’m also a co-founder of BiopharmaTrend.com, a UK-based media platform covering technological and business trends in the life sciences.

Over the past decade, I’ve helped build, scale, and manage digital ventures, including leadership in growing EnamineStore.com, now the world’s largest online marketplace for fine chemicals used in drug discovery.

My technical and business background includes:

- PhD in Physical Chemistry

- Academic research in coordination & bioinorganic chemistry, nanotechnology, sensors, materials, and surface science

- Industry-driven self-education in medicinal chemistry, molecular biology, computational drug discovery, ML-based methods, and LLMs

- Entrepreneurial experience across Ukraine, the US, Belgium, Indonesia, the UK, and Spain

If you’re building or investing in science-driven technology and need credible visibility, sharper positioning, or executive-level thought leadership, feel free to reach out here or at www.andriibuvailo.com.

Andrii Buvailo, Ph.D.

📢 A new paper suggests that a plain-language text prompt may soon be enough to launch an end-to-end drug discovery program...  

In a new paper, co-authored by Alex Zhavoronkov and David Gennert, PhD, (Insilico Medicine) and Jiye Shi (Eli Lilly and Company), researchers conceptualize a drug discovery paradigm in which a text prompt can initiate an end-to-end drug development program, from target discovery to a clinical-ready candidate.

In "From Prompt to Drug: Toward Pharmaceutical Superintelligence", the authors describe how modern drug discovery already can benefit from AI at nearly every step, including omics-driven target identification, generative molecular design, docking and ADMET prediction, retrosynthesis planning, automated synthesis, and even clinical trial modeling. 

☝ The problem, they argue, is not a lack of capability but a lack of integration. 

These systems operate in silos, with humans coordinating handoffs between tools, labs, and teams, creating delays, errors, and bias. Their proposed solution is an AI-orchestrated "system-of-systems". 

Large language models with advanced reasoning capabilities act as central controllers: planning workflows, coordinating specialized AI agents, calling physics-based models (molecular dynamics, docking, QM), and interfacing with automated laboratories via APIs. Rather than generating molecules directly and hoping for the best, the system runs closed-loop design–make–test–analyze cycles, where experimental results continuously feed back into model refinement.

The paper is explicit about technical constraints, though. LLMs alone lack biochemical grounding, suffer from hallucinations, and can propagate errors across pipeline stages. 

To mitigate this, the authors emphasize hybrid architectures combining language-based planning with structure-aware models, ensemble validation between agents, confidence propagation, backtracking, and mandatory human-in-the-loop checkpoints for high-stakes decisions such as clinical trial design.

They refer to the long-term outcome as Pharmaceutical Superintelligence. It is not a single model, but a coordinated, multimodal platform trained on omics data, molecular structures, experimental results, and clinical outcomes, capable of autonomously running large portions of drug discovery while remaining auditable and regulator-aligned.

It is a thought-provoking read, and I am curious to read your thoughts about it. While the idea might seem futuristic to some, Insilico Medicine demonstrated a track record of fast-paced drug discovery programs reaching clinical milestones... so while none of their programs are FDA approved yet, they are certainly trying hard to build this vision, it seems... time will tell. 

Image credit: authors of the paper

Science & Tech Communicator | AI & Digital | Life Sciences | Chemistry

taplio

The Battle

Basem Goueli MD/PhD/MBA

Andrii Buvailo, Ph.D.

Followers

Posts

Engagements

Likes

Performance ScoreAndrii Buvailo, Ph.D.'s LinkedIn Performance

Ready to grow your LinkedIn presence?

taplio

The Battle

Basem Goueli MD/PhD/MBA

Andrii Buvailo, Ph.D.

Followers

Posts

Engagements

Likes

Performance Score.css-goub6s{font-size:var(--chakra-fontSizes-md);font-weight:500;color:var(--chakra-colors-gray-600);display:block;margin-top:var(--chakra-space-1);}Andrii Buvailo, Ph.D.'s LinkedIn Performance

Ready to grow your LinkedIn presence?

Performance ScoreAndrii Buvailo, Ph.D.'s LinkedIn Performance